Clinical cancer vaccine trials

Current Opinion in Immunology

Volumn 14, Issue 2, 2002, Pages 178-182

  Jäger, Elke ^a   Jäger, Dirk ^a   Knuth, Alexander ^a  

^a II Medizinische Klinik   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; FREUND ADJUVANT; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOPHENOL MONOOXYGENASE; NAKED DNA; QS 21; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; VIRUS PROTEIN;

ADENOVIRUS; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; CANCER; CANCER CELL; CANCER PREVENTION; CELLULAR IMMUNITY; CLINICAL TRIAL; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; DRUG SCREENING; FOWLPOX VIRUS; GENETIC CODE; GENETIC TRANSFECTION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; LANGERHANS CELL; REVIEW; T LYMPHOCYTE; VACCINATION; VACCINIA VIRUS;

EID: 0036533438     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(02)00318-7     Document Type: Review

References (42)

1. Progress in human tumour immunology and immunotherapy
2. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
3. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes
4. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
5. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening
6. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
7. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines
8. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
9. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: Implications for tumor vaccines with melanoma-associated antigens
10. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo
11. + cancers
12. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
13. Oncogenic proteins as tumor antigens
14. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine
15. Human papillomavirus vaccines for cervical cancer
16. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes
17. + T cells
18. CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: Association with NY-ESO-1 antibody production
19. + T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene
20. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma
21. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma
22. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma
23. Delayedtype hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization
24. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3
25. Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides
26. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL
27. + T-cell response to NY-ESO-1: Relative antigenicity and in vitro immunogenicity of natural and analogue sequences
28. Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen
29. Tumour-associated antigen (TAA)-specific cytotoxic T cell (CTL) response in vitro and in a mouse model, induced by TAA-plasmids delivered by influenza virosomes
30. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine
31. Vaccination with MAGE-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
32. Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors
33. Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA
34. Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients
35. Frequency analysis of tumor-reactive cytotoxic T lymphocytes in peripheral blood of a melanoma patient vaccinated with autologous tumor cells
36. Monitoring CD8 T cell responses to NY-ESO-1: Correlation of humoral and cellular immune responses
37. HLA-peptide tetrameric complexes
38. Discrepancy between ELISPOT IFN-gamma secretion and binding of A2/peptide multimers to TCR reveals interclonal dissociation of CTL effector function from TCR-peptide/MHC complexes half-life
39. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
40. + T cells after vaccination with antigenic peptide
41. Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma
42. Analysis of HLA class I expression in different metastases from two melanoma patients undergoing peptide immunotherapy